Novocure to Offer On Demand Optune Certification Training for the Radiation Oncology Community at ASTRO 2015

Optune is the first FDA-approved therapy in more than a decade to demonstrate statistically significant extension of survival in newly diagnosed glioblastoma patients ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR), a commercial stage oncology company pioneering a novel therapy for solid tumors, announced today it will offer on demand Optune certification training for the radiation oncology …

Novocure to Report Third Quarter 2015 Financial Results on Monday, October 26

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR), a commercial stage oncology company pioneering a novel therapy for solid tumors, announced today that it will report financial results for the third quarter of 2015 on Monday, October 26, 2015 after the close of U.S.-based financial markets. Following the announcement, Novocure management will host a conference call and …

ADDING MULTIMEDIA FDA Approves Optune in Combination with Temozolomide for the Treatment of Newly Diagnosed Glioblastoma

Optune is the first FDA-approved therapy in more than a decade to demonstrate statistically significant extension of survival in newly diagnosed glioblastoma patients ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) has approved Optune in combination with temozolomide for the treatment of adult patients with newly diagnosed …

NovoCure Limited Announces Closing of Initial Public Offering

ST. HELIER, Jersey–(BUSINESS WIRE)–NovoCure Limited (NASDAQ: NVCR), a commercial stage oncology company pioneering a novel therapy for solid tumors, announced today the closing of its initial public offering of 7,500,000 ordinary shares at a price to the public of $22 per share. In addition, the underwriters for the offering have a 30-day option, commencing on …

Novocure Announces CE Mark and First Patient Use of Second Generation Optune System

The newly designed, second generation Optune system incorporates state of the art digital technology and is more than 50% lighter and 50% smaller than the first generation system ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ:NVCR), a commercial stage oncology company, announced today the placement of the CE mark on, and first patient use of, the newly designed …

NovoCure Limited Announces Launch of Initial Public Offering

ST. HELIER, Jersey–(BUSINESS WIRE)–NovoCure Limited, a commercial stage oncology company pioneering a novel therapy for solid tumors, announced today the launch of its initial public offering of 12,500,000 shares of its common stock, including 7,500,000 shares to be sold by NovoCure Limited and 5,000,000 shares to be sold by selling shareholders. The initial public offer …

NovoCure Limited Announces Launch of Initial Public Offering

ST. HELIER, Jersey–(BUSINESS WIRE)–NovoCure Limited, a commercial stage oncology company pioneering a novel therapy for solid tumors, announced today the launch of its initial public offering of 12,500,000 shares of its common stock, including 7,500,000 shares to be sold by NovoCure Limited and 5,000,000 shares to be sold by selling shareholders. The initial public offer …

Novocure to Present the Latest Data from the EF-14 Clinical Trial in Newly Diagnosed GBM at the 15th Interim Meeting of the World Federation of Neurosurgical Societies

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure, a commercial stage oncology company, announced today that the latest data from the EF-14 randomized phase 3 trial of Tumor Treating Fields (TTFields) in newly diagnosed glioblastoma (GBM) will be presented by Professor Zvi Ram, Head of the Department of Neurosurgery, Tel Aviv Medical Center, Israel, in an oral session at …

Novocure Announces Optune Now Available at more than 200 Leading Cancer Centers across the United States

Optune, a Tumor Treating Fields delivery system, provides a novel, non-invasive treatment for recurrent glioblastoma, the most common and deadly malignant primary brain cancer NEW YORK–(BUSINESS WIRE)–Novocure announced today that more than 200 treatment centers in the United States have been certified to prescribe Optune to patients with recurrent glioblastoma (GBM). GBM is the most …

Novocure to Present Clinical Trial Designs and Preclinical Data on Tumor Treating Fields at the 16th World Conference on Lung Cancer

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure, a commercial stage oncology company, announced today that its ongoing and future clinical trial designs in lung cancer will be presented at the 16th World Conference on Lung Cancer (WCLC). The WCLC is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, organized by the International Association for …